Checkpoint inhibition has revolutionized cancer treatment, offering hope to patients with various malignancies. However, its efficacy in solid tumors remains limited, with response rates often below 15% (1). This article explores the challenges that make checkpoint inhibition an ineffective strategy for many solid tumors and discusses the need for alternative approaches. 1. The Tumor Microenvironment: … Continue reading Why Checkpoint Inhibition Struggles in Solid Tumor Treatment